COVID-Influenza Combination (CIC) — Novavax

Phase 3 Clinical Trial

Developer: Novavax  |  Target Disease: Seasonal influenza + COVID-19 (combination)

Category Resource

Explore licensed vaccines, adverse event reporting data, and history for this disease.

View Seasonal influenza + COVID-19 (combination) Vaccine Guide →
  1. Phase 1
  2. Phase 2
  3. Phase 3
  4. Filed
  5. Approved
Development Phase Phase 3 Clinical Trial Primary Status
Platform Technology Protein nanoparticle + Matrix-M Biologic Architecture
Target Indication Seasonal influenza + COVID-19 (combination) Pathogen / Antigen
Last Verified 2026-07-10 Tier 1 Multi-Source Checked

Multi-Jurisdiction Regulatory Status

Official licensing, rolling submissions, or authorization status tracked across major health authorities.

Regulatory Authority Status & Details
US FDA Phase 3 Date as recorded by the curator: "verify on ClinicalTrials.gov / company pipeline"
EMA (Europe) Not Filed / Pre-submission
Health Canada Not Filed / Pre-submission
TGA (Australia) Not Filed / Pre-submission

Progress and adoption outlook

Where this candidate sits on a fixed development ladder, and when a licence and a routine-use recommendation could follow in each jurisdiction, as scenario bands. Input grade: Stage known from the trial registry only; no jurisdiction-specific filing date.

60% of the ladderC · registry only
  1. Preclinical
  2. Phase 1
  3. Phase 1/2
  4. Phase 2
  5. Phase 2/3
  6. Phase 3
  7. Submitted to a regulator
  8. Under regulatory review
  9. Approved / authorised
  10. Recommended for routine use

Current position: Phase 3

Status and projected windows by jurisdiction
JurisdictionStatus in the recordSubmissionRegulator decisionEarliest routine use
United StatesFDA (CBER) · ACIP (CDC)phase 32027-072027-01 to 2028-042028-052027-07 to 2029-072028-082027-07 to 2030-03
European UnionEMA (CHMP) and European Commission · national bodies (STIKO, HAS, Folkhälsomyndigheten and others)no jurisdiction-specific filing known2027-072027-01 to 2028-042028-092027-10 to 2029-122029-032027-11 to 2031-06
CanadaHealth Canada · NACIno jurisdiction-specific filing known2027-072027-01 to 2028-042028-052027-07 to 2029-072028-092027-08 to 2030-07
United KingdomMHRA · JCVIno jurisdiction-specific filing knownThe MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used.
AustraliaTGA · ATAGIno jurisdiction-specific filing knownTGA registration-timeframe pages timed out on 2026-10-24; no target is used.
JapanPMDA / MHLW · MHLW immunisation subcommitteeno jurisdiction-specific filing knownPMDA English pages reached on 2026-10-24 state that target review times exist but give no figure.
WHO prequalificationWHO Prequalification · SAGEno jurisdiction-specific filing knownWHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used.

Each window shows the typical scenario with the fast-to-slow band beneath it (year-month). Bands come from the parameters on the outlook model page; they are not forecasts.

Scientific Profile & Documentation

Platform Architecture
Protein nanoparticle + Matrix-M
Lead Developer
Novavax
Next Expected Milestone
Phase 3 data and potential regulatory path (company projection — verify latest filings)

Registered Clinical Trials & Studies

Direct registry links to active, completed, or pivotal registration studies across phases.

No primary ClinicalTrials.gov record linked directly. Study data tracked via regulatory submission filings and peer-reviewed releases.

Milestone Overview

  • Stage Verification
    Phase 3 Clinical Trial confirmed as of 2026-07-10.
  • Target Milestone
    Phase 3 data and potential regulatory path (company projection — verify latest filings)

Vaccine Data Navigator Candidate Profile Registry:

This candidate profile is indexed across all clinical development levels (Preclinical through Phase 1–3, Regulatory Filing, and Licensure) from primary registry databases (ClinicalTrials.gov, WHO ICTRP, FDA CBER, EMA, Health Canada, TGA Australia). Data are updated continuously to track global biologic and vaccine pipelines.